Rituximab in lymphocyte-predominant Hodgkin's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1400, 2003-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3387-3389

Blackwell Publishing

Access to resources Recommend Favorite

Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3472-3480

Blackwell Publishing

Access to resources Recommend Favorite

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma

By  

Hematological Oncology (Electronic), Vol. 33, Iss. S1, 2015-06 ,pp. : 90-95

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 116-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab: Hodgkin's disease: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1283, 2010-01 ,pp. : 80-81

Adis International

Access to resources Recommend Favorite